Real-time insights. Smarter decisions. Better trades.
🔍 Search Stocks 14 day Free Trial
IMMUTEP LIMITED (IMM)ASX AI Signals has generated 0 signals for IMM during the last 90 days, indicating low trading activity
IMM Share Price | |
| Current Price | $0.055 |
| 52 Week High | $0.460 |
| 52 Week Low: | $0.036 |
| Trading at (% of 52 Week High) | 11.96% |
Immutep Limited (ASX: IMM) is a biotechnology company focused on developing immunotherapy treatments for cancer and autoimmune diseases. The company specializes in LAG-3-based therapies designed to enhance the immune system's ability to fight disease. Immutep conducts clinical trials to advance its pipeline of drug candidates.
The Pharmaceuticals, Biotechnology & Life Sciences sector on the ASX includes companies involved in the development, production, and commercialization of drugs, medical devices, and biotechnology products. This sector covers activities such as research and development of new medicines, genetic testing, and innovative healthcare technologies. Companies often work on treatments for diseases, including cancer, infectious diseases, and chronic conditions. The sector plays a crucial role in advancing medical science and improving patient care through innovation.
IMMUTEP LIMITED shows potential for growth given its focus on immunotherapy, but the low stock price and inherent biotech sector volatility suggest moderate confidence in a BUY recommendation.
The Australian market recently experienced a dip, with the ASX down 0.3% as investors awaited key CPI data and closely monitored geopolitical developments, such as the US-China diplomatic talks. In this environment of cautious optimism and sector fluctuations, identifying high-growth tech stocks req Immutep Limited
Global Phase III trial has enrolled and randomised over 170 patients, reaching an important milestone as this is above the amount needed to conduct the futility analysis Over 100 clinical sites across 24 countries now activated and open for recruitment
Futility analysis remains on As the Australian market navigates a fluctuating landscape, with the S&P/ASX 200 Index recently flirting with 8,860 points and foreign direct investment outflows heading back to the US, investors are keenly evaluating high-growth opportunities amid shifting sentiments. In this context, identifying p Immutep Limited
SYDNEY, AUSTRALIA, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces it has received positive and constructive feedback from the US Foo Immutep Limited
SYDNEY, AUSTRALIA, July 29, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces an upcoming poster presentation for the pivotal TACTI-004 (KEYNOTELatest IMMUTEP LIMITED(IMM) News
Exploring 3 High Growth Tech Stocks In Australia
Immutep Announces Update for TACTI-004 (KEYNOTE-F91) Phase III Trial in First Line Non-Small Cell Lung Cancer
Altium And 2 Other High Growth Tech Stocks In Australia
Immutep Receives Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alfa in Head and Neck Cancer with CPS <1
Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the 2025 World Conference on Lung Cancer
Get access to daily BUY & SELL signals, advanced AI analysis, watchlists and email alerts.
14 Day Free Trial • Cancel Anytime • Founders Price $15/month
Start My Free Trial